Generation Bio (GBIO)
(Real Time Quote from BATS)
$2.94 USD
-0.05 (-1.67%)
Updated Apr 25, 2024 11:24 AM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GBIO 2.94 -0.05(-1.67%)
Will GBIO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GBIO
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
GBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
Can Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect?
Other News for GBIO
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Poseida Therapeutics (PSTX)
Commit To Purchase Generation Bio Co At $2.50, Earn 28.9% Annualized Using Options
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference